Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/10/2025

Treatment-Resistant Depression Management with Esketamine and Anxiety Treatment

Esketamine Safety and Efficacy

  • The VA/DoD guidelines support esketamine as a treatment option for patients who have failed at least 2 adequate antidepressant trials, which is applicable to patients with treatment-resistant depression 1, 2
  • Continuing esketamine twice weekly for nearly one year is supported by available evidence and appears safe based on long-term studies, though documented objective improvement on standardized depression scales is necessary to justify continuation 1, 2
  • Critical requirement: A 50% reduction in PHQ-9 or MADRS scores from baseline is necessary to justify continuation beyond the acute phase 1
  • Blood pressure monitoring during each administration session is mandatory due to transient hypertensive effects 2

Anxiety Management

  • Buspirone augmentation of antidepressants showed no difference in response or remission compared to bupropion augmentation in the STAR*D trial, though bupropion reduced depression severity more effectively 3, 4
  • The American Academy of Child and Adolescent Psychiatry recommends starting buspirone at 7.5 mg twice daily, titrating to 15-30 mg twice daily over 2-3 weeks while maintaining Rexulti, then reassessing after 6-8 weeks of therapeutic dosing before considering Rexulti taper 5
  • SNRIs (venlafaxine, duloxetine) are first-line alternatives when SSRIs fail for generalized anxiety, with moderate evidence for efficacy 3, 4
  • Abrupt discontinuation of atypical antipsychotics can cause withdrawal symptoms and rebound anxiety, so tapering by 25% every 1-2 weeks is recommended while monitoring for symptom recurrence 5

ADD Medication Optimization

  • The American Academy of Child and Adolescent Psychiatry suggests considering increasing Concerta to 72 mg (maximum FDA-approved dose) and reassessing after 1 week, or switching back to Adderall with dose optimization (potentially 40-60 mg daily in divided doses) 5
  • Lisdexamfetamine (Vyvanse) provides a smoother, longer-lasting effect than immediate-release Adderall and may be less susceptible to fluctuations 5
  • Non-stimulant alternatives like atomoxetine or bupropion can augment stimulants without interaction concerns, though they provide less robust ADD symptom control 3, 4

Zoloft Tapering

  • The American Academy of Child and Adolescent Psychiatry recommends reducing sertraline by 25-50 mg every 1-2 weeks, monitoring for withdrawal symptoms, with slower taper (every 2-4 weeks) if discontinuation symptoms occur 5
  • Continuing esketamine throughout the Zoloft taper is necessary to maintain antidepressant coverage, as esketamine's rapid-acting mechanism can help bridge the transition 2